As noted by researchers within the Harvard Stem Cell Institute, researchers obtained fibroblasts from a mouse with sickle cell anemia and, using a virus, "reprogrammed these cells into pluripotent [stem cells], corrected the genetic deficiency by homologous recombination, and redirected these pluripotent cells toward the hematopoietic lineages, and transplanted these engineered cells to a lethally irradiated mice."[1] The animals which received the fibroblast stem cell treatment exhibited increased activity levels, indicating recovery from the disorder.[7]